Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Halozyme Therapeutics has a Zacks #1 (Strong Buy) rating and a +2.78% Earnings ESP, based on a $2.34 most accurate EPS estimate versus a $2.28 consensus, ahead of its November 2, 2026 earnings release. United Therapeutics has a #3 (Hold) rating and a +1.52% ESP, with estimates of $6.35 versus $6.26 consensus, ahead of its November 4 report. The article says positive ESP combined with a Zacks Rank of #3 or better produced positive earnings surprises 70% of the time in a 10-year backtest; neither company has yet reported the cited results.

Analysis

The actionable signal is weak: the reported estimate gaps are small and, using the article’s figures, do not exactly match its stated ESPs (HALO: about 2.6% versus 2.78%; UTHR: about 1.4% versus 1.52%). These gaps can disappear with routine estimate updates and say little about the size or quality of any earnings beat. The cited backtest is not a forecast of these stocks’ event returns; the article provides no detail on sample construction, costs, risk adjustment, or performance around comparable releases.

Near term (days to the Nov. 2 and Nov. 4 releases), the main risk is an expectations trade: a small beat may not support shares if guidance, forward estimates, or other reported metrics disappoint. A miss or cautious outlook could produce asymmetric downside if investors positioned for a beat, but positioning and options-implied moves are not provided. There is no basis here for a HALO/UTHR pair: the shared healthcare label does not establish comparable businesses or earnings drivers.

Over 1–3 months, confirm the actual EPS result, guidance, and post-release analyst revisions before treating the estimate signal as durable. Over 6–18 months, this article supplies no evidence about product economics, competitive position, or structural growth; do not extrapolate the screen into a long-term thesis. The contrarian point is that the promotional framing may overstate a modest, noisy revision signal. No trade is warranted on this evidence alone.

Key Decisions for Investors

• Do not initiate a pre-earnings long in HALO or UTHR solely on the reported ESPs; the signal is small, and its stated values do not reconcile exactly with the quoted estimates.
• Before either release, verify the current consensus and most-accurate estimates, the date and scope of each EPS figure, and the options-implied move. Treat an options position as a watch item until those data are available.
• Reassess after earnings: a positive surprise accompanied by maintained or raised forward guidance and upward estimate revisions would support a follow-up long; an EPS beat with weaker guidance or falling estimates would falsify the bullish read.
• Avoid a HALO-versus-UTHR pair trade absent evidence that their earnings drivers and valuation exposures are comparable.